Bibliometric analysis of N6-methyladenosine in cancer: landscapes, highlights and trending topics-Reference-Cited by-同舟云学术

Bibliometric analysis of N6-methyladenosine in cancer: landscapes, highlights and trending topics

Published:2022-06 Issue:17 Volume:18 Page:2141-2153
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Jiang Haotian¹^ORCID,Li Yuan²,Liu Yinghui¹,Dong Weiguo¹

Affiliation:

1. Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China

2. Department of Oncology, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, China

Abstract

Background: N6-methyladenosine (m6A) is crucial in cancer and is being intensively studied. Aim: This bibliometric analysis seeks a broad picture of the role of m6A in cancer to guide and broaden future research. Methods: Publications were retrieved from Web of Science Core Collection and PubMed from 2000 to 2021, with keywords ‘m6A’ and ‘cancer’, and analyzed in biblioshiny and VOSviewer. Results: A total of 1013 documents were included, and China and the USA were the top countries with close collaboration. Mechanisms and predictive biomarkers of m6A regulator genes were highlighted. Cross-integration of m6A and other research hot spots, including ‘immunotherapy’, ‘hypoxia' and ‘polymorphism’, were frontiers of m6A in cancer. Conclusion: This bibliometric study offered an updated perspective on m6A in cancer.

Funder

National Natural Science Foundation of China

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-0086

Reference26 articles.

1. RNA-modifying proteins as anticancer drug targets

2. A panoramic view of RNA modifications: exploring new frontiers

3. N6-methyladenosine–encoded epitranscriptomics

4. The RNA code comes into focus

5. Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome